Lucid Diagnostics (LUCD) to Release Earnings on Thursday

Posted by George Bondi on May 12th, 2026

Lucid Diagnostics (NASDAQ:LUCD – Get Free Report) is anticipated to release its Q1 2026 results before the market opens on Thursday, May 14th. Analysts expect the company to announce earnings of ($0.05) per share and revenue of $1.38 million for the quarter. Investors can find conference call details on the company’s upcoming Q1 2026 earning report page for the latest details on the call scheduled for Thursday, May 14, 2026 at 8:30 AM ET.

Lucid Diagnostics (NASDAQ:LUCD – Get Free Report) last announced its quarterly earnings results on Wednesday, March 25th. The company reported ($0.10) EPS for the quarter, missing analysts’ consensus estimates of ($0.07) by ($0.03). The firm had revenue of $1.50 million during the quarter, compared to the consensus estimate of $1.39 million. On average, analysts expect Lucid Diagnostics to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Lucid Diagnostics Stock Performance

NASDAQ LUCD opened at $1.02 on Tuesday. The business has a 50 day simple moving average of $1.23 and a 200 day simple moving average of $1.19. Lucid Diagnostics has a 52-week low of $0.95 and a 52-week high of $1.70. The stock has a market cap of $199.16 million, a price-to-earnings ratio of -1.06 and a beta of 1.10.

Wall Street Analyst Weigh In

A number of research firms recently issued reports on LUCD. Ascendiant Capital Markets upped their price target on Lucid Diagnostics from $8.25 to $9.00 and gave the stock a “buy” rating in a research report on Thursday, April 9th. Wall Street Zen downgraded Lucid Diagnostics from a “hold” rating to a “sell” rating in a report on Saturday. Needham & Company LLC reaffirmed a “buy” rating and set a $3.00 price target on shares of Lucid Diagnostics in a report on Thursday, March 26th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Lucid Diagnostics in a report on Wednesday, May 6th. Finally, BTIG Research reiterated a “buy” rating and set a $2.50 price objective on shares of Lucid Diagnostics in a research report on Monday, March 30th. Four analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $4.13.

Read Our Latest Analysis on Lucid Diagnostics

Institutional Trading of Lucid Diagnostics

A number of hedge funds have recently made changes to their positions in LUCD. Centiva Capital LP acquired a new stake in shares of Lucid Diagnostics during the third quarter valued at about $25,000. Abel Hall LLC bought a new stake in Lucid Diagnostics in the fourth quarter worth approximately $33,000. JPMorgan Chase & Co. increased its holdings in Lucid Diagnostics by 71,026.1% in the second quarter. JPMorgan Chase & Co. now owns 32,718 shares of the company’s stock worth $38,000 after purchasing an additional 32,672 shares in the last quarter. Cubist Systematic Strategies LLC bought a new stake in Lucid Diagnostics in the first quarter worth approximately $39,000. Finally, Invesco Ltd. bought a new stake in Lucid Diagnostics in the second quarter worth approximately $41,000. 74.01% of the stock is owned by institutional investors and hedge funds.

About Lucid Diagnostics

(Get Free Report)

Lucid Diagnostics is a molecular diagnostics company focused on improving early detection of oral and oropharyngeal cancers. The company’s flagship offering, the LucidDx Oral Cytology Brush Test, combines a minimally invasive brush biopsy tool with proprietary laboratory analysis to identify cellular abnormalities indicative of malignancy. Samples collected in dental and medical offices are sent to Lucid’s CLIA-certified and CAP-accredited laboratory, where advanced imaging and cytopathology workflows generate diagnostic reports for clinicians and patients.

Since commencing commercial operations, Lucid Diagnostics has worked to integrate its testing platform into dental practices, oral surgery clinics and ENT specialists across the United States.